MarketScreener Homepage > Equities > Xetra > Evotec SE EVT DE0005664809

Report

Real-time Estimate Tradegate - 11/27 03:59:59 pm
25.645	EUR		+0.96%

11/25

EVOTEC : and Rappta Therapeutics enter discovery and development partnership focused on oncology target

11/24

EVOTEC : And rappta therapeutics enter discovery and development partnership focused on oncology target

11/20

EVOTEC : presents growth drivers of 'Autobahn to Cures' at Capital Markets Day

Summary

Quotes 5-day view Delayed Quote.

Delayed Xetra

11/23/2020	11/24/2020	11/25/2020	11/26/2020	11/27/2020	Date
25.34(c)	24.98(c)	24.96(c)	25.4(c)	25.74	Last
417 601	541 780	367 376	386 218	585 780	Volume
+0.76%	-1.42%	-0.08%	+1.76%	+1.34%	Change

More quotes

Financials

Sales 2020	475 M 568 M 568 M
Net income 2020	26,4 M 31,6 M 31,6 M
Net cash position 2020	7,50 M 8,96 M 8,96 M
P/E ratio 2020	177x
Yield 2020	-

Sales 2021	549 M 656 M 656 M
Net income 2021	44,6 M 53,3 M 53,3 M
Net cash position 2021	68,5 M 81,9 M 81,9 M
P/E ratio 2021	89,5x
Yield 2021	-

Capitalization	4 202 M 5 024 M 5 022 M
EV / Sales 2020	8,83x
EV / Sales 2021	7,53x
Nbr of Employees	3 444
Free-Float	90,7%

More Financials

Company

Evotec SE specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment; - other: target identification, pharmacological tests development, broadband screening...

Sector

Biotechnology & Medical Research

Calendar

12/02 | 04:00pm

Präsentation

More about the company

Notations Surperformance© of Evotec SE

Trading Rating :

Investor Rating :

More Ratings

All news about EVOTEC SE

11/25	EVOTEC : and Rappta Therapeutics enter discovery and development partnership foc..	AQ
11/24	EVOTEC : And rappta therapeutics enter discovery and development partnership foc..	EQ
11/20	EVOTEC : presents growth drivers of 'Autobahn to Cures' at Capital Markets Day	AQ
11/20	EVOTEC : Gets a Buy rating from RBC	MD
11/19	EVOTEC : Presents growth drivers of 'autobahn to cures' at capital markets day	EQ
11/18	EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..	AQ
11/17	EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..	PU
11/17	EVOTEC : And storm therapeutics leverage indigo platform to progress oncology pr..	EQ
11/16	EVOTEC SE : Notification and public disclosure of transactions by persons	EQ
11/13	EVOTEC : Deutsche Bank reiterates its Buy rating	MD
11/13	EVOTEC : expands Oxfordshire site into a fully-integrated R&D centre named 'Doro..	AQ
11/12	EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..	EQ
11/12	EVOTEC : Receives a Buy rating from Baader Bank	MD
11/12	EVOTEC : RBC keeps its Buy rating	MD
11/12	EVOTEC : expands Oxfordshire site into a fully-integrated R&D centre named "Doro..	PU

More news

News in other languages on EVOTEC SE

11/24	EVOTEC : Und rappta therapeutics gehen auf onkologie-target fokussierte forschun..
11/24	Evotec und rappta therapeutics gehen auf onkologie-target fokussierte forschu..
11/20	EVOTEC : RBC à l'achat
11/20	RBC hebt Ziel für Evotec auf 32 Euro - 'Outperform'
11/19	EVOTEC : präsentiert Wachstumstreiber der "Autobahn to Cures" auf dem Capital Ma..

More news

Analyst Recommendations on EVOTEC SE

11/20	EVOTEC : Gets a Buy rating from RBC	MD
11/13	EVOTEC : Deutsche Bank reiterates its Buy rating	MD
11/12	EVOTEC : Receives a Buy rating from Baader Bank	MD

More recommendations

Stock Trading Strategies

	EVOTEC SE - 07/24
Back on price levels to sell

SELL

More Stock Trading Analysis

Provided by Scoopnest.com

Chart EVOTEC SE

Duration : Period :

Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener

Full-screen chart

Technical analysis trends EVOTEC SE

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	9
Average target price	30,67 €
Last Close Price	25,40 €
Spread / Highest target	41,7%
Spread / Average Target	20,7%
Spread / Lowest Target	10,2%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Werner Lanthaler	Chief Executive Officer
Wolfgang Plischke	Chairman-Supervisory Board
Craig L. Johnstone	Chief Operating Officer & Member-Management Board
Enno Spillner	Chief Financial Officer
Cord E. Dohrmann	Chief Scientific Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

EVOTEC SE	10.20%	4 937



LONZA GROUP AG	55.15%	44 901
MODERNA, INC.	458.18%	43 204
CELLTRION, INC.	82.04%	39 811
IQVIA HOLDINGS INC.	9.94%	32 568
SEAGEN INC.	44.80%	29 832

More Results